Key Summary Points {#FPar1}
==================

***Why carry out this study?***In cystic fibrosis (CF), a life-shortening, rare genetic disease, researchers have the unique opportunity to evaluate data from the majority of patients in their respective regions collected by national CF registries, with the US Cystic Fibrosis Foundation Patient Registry (US CFFPR) and the UK Cystic Fibrosis Registry (UK CFR) being the largest.To evaluate disease progression and clinical outcomes in patients treated with ivacaftor (the first approved CF transmembrane conductance regulator \[CFTR\] modulator targeting the underlying cause of CF), we conducted a long-term observational study comparing outcomes in patients in the US and UK registries who were treated with ivacaftor versus matched untreated comparator patients.This study asked, "Among patients with CF treated with ivacaftor in real-world clinical practice, what are the patterns in key clinical outcomes?"***What was learned from the study?***Analyses of up to 5 years of experience with ivacaftor in real-world clinical practice across countries and years identified no new safety concerns and demonstrated consistently favorable outcomes in ivacaftor-treated patients.These data support the conclusion that highly effective CFTR modulation with ivacaftor leads to disease modification, consistent with the multisystem benefits observed in clinical trials.

Introduction {#Sec1}
============

Real-world data provide information about long-term safety and effectiveness of treatments outside of clinical trials; the value of such data is increasingly recognized as real-world analysis methodologies become more rigorous \[[@CR1]\]. Disease registries are a valuable source of real-world data and are useful to evaluate benefits and risks of medicines \[[@CR2]\]. In cystic fibrosis (CF), a life-shortening, rare genetic disease, researchers have the unique opportunity to evaluate data from the majority of patients in their respective regions collected by national CF registries, with the US Cystic Fibrosis Foundation Patient Registry (US CFFPR) and the UK Cystic Fibrosis Registry (UK CFR) being the largest \[[@CR3]--[@CR6]\]. These registries provide a window into long-term outcomes in patients in the real-world setting \[[@CR7], [@CR8]\].

To evaluate disease progression and clinical outcomes in patients treated with the first approved CF transmembrane conductance regulator (CFTR) modulator targeting the underlying cause of CF, we conducted a long-term observational study comparing outcomes in patients in the US and UK registries who were treated with ivacaftor versus matched untreated comparator patients \[[@CR7], [@CR8]\]. This postauthorization safety surveillance study was designed to fulfill a postmarketing commitment to the European Medicines Agency and is disclosed on the European Union electronic Register of Post-Authorization Studies (EUPAS4270) \[[@CR7], [@CR8]\]. Following previous reports, including the previously published disease progression analyses \[[@CR7], [@CR8]\], we report final results of the annual cross-sectional safety analyses across the duration of the study. These data provide insights to address the aim of assessing patients' long-term outcomes with highly effective CFTR modulation with ivacaftor in real-world clinical practice.

Methods {#Sec2}
=======

Study Population and Analysis Cohorts {#Sec3}
-------------------------------------

The study populations have been previously described \[[@CR7], [@CR8]\]. Starting in the first year of ivacaftor availability (2012 in the United States; 2013 in the United Kingdom), ivacaftor-treated patients in the US CFFPR and UK CFR were matched 1:5 by age, sex, and *CFTR* mutation genotype severity (predominantly classes I--III) to comparator patients who never received ivacaftor. Outcomes in ivacaftor versus comparator cohorts were analyzed separately in each registry, both in annual cross-sectional safety analyses (focusing on patient outcomes during a single year; Fig. 1) and in longitudinal analyses of disease progression outcomes over time \[[@CR7], [@CR8]\]. The annual cross-sectional safety analyses were conducted based on patients included in the annual safety cohorts: the ivacaftor safety cohort in the first year of the study included all patients treated with ivacaftor in the first year of availability; the ivacaftor safety cohort in subsequent years' analyses included patients who were members of the ivacaftor safety cohort the preceding year, were still alive, continued to receive ivacaftor, and remained in the registry at the beginning of the year, as well as any patients with a new record of ivacaftor treatment during that analysis year. Similarly, the annual comparator safety cohorts included patients who were members of the same cohort the previous year, were still alive, had no record of ivacaftor or lumacaftor/ivacaftor use, and remained in the registry at the beginning of the year, as well as new patients (with no record of ivacaftor or lumacaftor/ivacaftor use) who were matched to the new patients in that year's ivacaftor safety cohort. In contrast, the longitudinal disease progression analyses focused on the disease progression cohorts, i.e., the subset of patients followed continuously from the first year of availability through study completion. Details and complete results from the longitudinal disease progression analyses have been reported elsewhere \[[@CR8]\].

Data Analysis {#Sec4}
-------------

Clinical endpoints evaluated in the annual cross-sectional safety analyses included death, organ transplants, pulmonary exacerbations, and hospitalizations; registry definitions rather than clinical trial definitions were used. Death was defined as evidence of a date of death in the respective registry database. Organ transplants were defined as evidence of organ transplant in the registry database, including heart/lung, lung alone, liver, kidney, and other transplants. Pulmonary exacerbations were defined as episodes requiring intravenous antibiotic use at home or in the hospital. Hospitalizations were defined differently across the two registries: in the US CFFPR, hospitalization data included patients hospitalized for any reason (pulmonary exacerbation, pulmonary complication, gastrointestinal complication, transplant-related, sinus infection, nontransplant surgery, or other reasons), whereas in the UK CFR, only hospitalizations for pulmonary exacerbation were collected.

Relative risks and 95% CIs, based on normal approximation, were calculated to compare the ivacaftor and comparator cohorts in each registry. If the expected frequency was \< 5 in ≥ 1 substratum of the contingency table, Fisher\'s exact *P* values were calculated in lieu of CIs. Cross-sectional analyses were performed separately for each registry due to differences in data capture.

Ethics Compliance {#Sec5}
-----------------

As this is an analysis of an existing de-identified dataset, it is exempt from institutional review board (IRB) approval. Data from the US CFFPR and the UK CFR were used in this study with permission of each registry. Patient information was obtained and maintained by the CF Trust (in the United Kingdom) and CF Foundation (in the United States) patient registries, which obtain informed consent as part of their registry enrollment procedures. In the United Kingdom, the CF Trust Patient Registry consent procedures have been agreed upon with the National Research Ethics Service. The registry is registered under the Data Protection Act (1998) and has Research Ethics Committee approval. In the United States, data for the CF Foundation registry are only collected at sites where IRB approval has been obtained and for subjects for whom consent or assent (as applicable) is obtained.

Results {#Sec6}
=======

The number of patients receiving ivacaftor therapy in the US CFFPR increased from 807 during year 1 (2012) to 1858 during year 5 (2016). In the UK CFR, the number of patients receiving ivacaftor therapy increased from 307 during year 1 (2013) to 462 during year 4 (2016). The number of patients in each safety cohort in each analysis year are shown in Table [1](#Tab1){ref-type="table"}.Table 1Annual safety cohort sample sizes20122013201420152016US CFFPR Ivacaftor safety cohort, *n*807999125617271858 Comparator safety cohort, *n*^a^40354932620073297316UK CFR Ivacaftor safety cohort, *n*NA307411432462 Comparator safety cohort, *n*NA1533206922012372*NA* not applicable^a^Increased rates of attrition were observed in the US comparator cohort in 2015 and 2016 and were primarily driven by the exclusion of patients with a new record of lumacaftor/ivacaftor therapy after it became commercially available in the United States in 2015

Results of all annual cross-sectional safety analyses were generally consistent across time and countries. Relative risks of death, organ transplant, pulmonary exacerbation, and hospitalization in the ivacaftor safety cohort versus the comparator safety cohort of each registry in each analysis year are shown in Table [2](#Tab2){ref-type="table"} along with the corresponding 95% CIs.Table 2Summary of key safety outcomes across US and UK annual analyses of ivacaftor versus comparator safety cohortsRelative risk (95% CI)/Fisher\'s exact *P* value^a^20122013201420152016US CFFPR Death0.43 (0.17, 1.07)0.37 (0.15, 0.93)0.41 (0.20, 0.84)0.18 (0.07, 0.44)0.41 (0.20, 0.86) Organ transplants0.22 (0.05, 0.89)0.19 (0.05, 0.76)0.15 (0.04, 0.59)0.55 (0.27, 1.09)0.29 (0.13, 0.67) Pulmonary exacerbation0.70 (0.62, 0.78)0.62 (0.56, 0.69)0.64 (0.58, 0.70)0.69 (0.63, 0.76)0.72 (0.66, 0.79) Hospitalizations^b^0.67 (0.60, 0.76)0.59 (0.53, 0.66)0.64 (0.58, 0.70)0.66 (0.60, 0.72)0.67 (0.62, 0.73)UK CFR DeathNA0.45, *P* = 0.410.52 (0.16, 1.70)0.75 (0.27, 2.15)0.47, *P* = 0.41 Organ transplantsNA0.76, *P* = 1.000.56, *P* = 0.56NA, *P* = 0.060.24, *P* = 0.20 Pulmonary exacerbationNA0.89 (0.79, 1.00)0.61 (0.53, 0.70)0.61 (0.53, 0.70)0.58 (0.50, 0.67) Hospitalization due to pulmonary exacerbationNA0.87 (0.75, 1.01)0.57 (0.48, 0.68)0.62 (0.53, 0.73)0.57 (0.48, 0.67)*NA* not applicable^a^Fisher\'s exact *P* values are shown when the expected value is \< 5 in ≥ 1 cell of the contingency table^b^Reasons for hospitalization included pulmonary exacerbation, pulmonary complication, gastrointestinal complication, transplant related, sinus infection, nontransplant surgery, and other

No new safety concerns with ivacaftor were identified. Favorable clinical outcomes across multiple endpoints were observed in patients treated with ivacaftor relative to untreated comparators; data show a pattern of lower risk of death, transplant, pulmonary exacerbation, and hospitalization among ivacaftor-treated patients in both registries. This is consistent with the previously reported preservation of lung function in ivacaftor-treated patients versus comparators \[[@CR8]\]. Overall, these results demonstrate the favorable impact of ivacaftor on several markers of CF disease.

Discussion {#Sec7}
==========

Analyses of up to 5 years of experience with ivacaftor in real-world clinical practice across countries and years identified no new safety concerns and demonstrated consistently favorable outcomes in ivacaftor-treated patients. These results are consistent with and build upon previous reports from this study \[[@CR7], [@CR8]\]. The first report from this study described results from the 2014 annual cross-sectional safety analysis (i.e., year 3 in the United States and year 2 in the United Kingdom) with similar results to those reported here \[[@CR7]\]; however, whereas that report described a single snapshot of data, we have now demonstrated that the observed favorable trends for ivacaftor treatment were durable and consistent across 4 to 5 years of analysis. Together, results from the annual cross-sectional safety analyses reported here and results from the long-term longitudinal disease progression analysis \[[@CR8]\] reinforce the favorable long-term outcomes of ivacaftor treatment, both in terms of patients' annual experience during each year of treatment and when considering their cumulative experience over time. These data support the conclusion that highly effective CFTR modulation with ivacaftor leads to disease modification, consistent with the multisystem benefits observed in clinical trials \[[@CR9]--[@CR12]\].

A lower risk of death was observed relatively early on and remained consistent each year. A similar finding was observed for the risk of organ transplant. Reductions in the annual risk of other clinically relevant outcomes, including hospitalizations and pulmonary exacerbations, were also observed. It should be emphasized that the beneficial patterns for all outcomes evaluated in this study were consistently observed across the analysis years in each registry, even though the annual relative risk estimates varied from year to year, which was not unexpected given the changing composition of cohorts included in each annual cross-sectional analysis inherent to the study design.

It should also be noted that all the outcome patterns were consistent between the two registries, even though there were differences in definitions used by the registries for some outcomes. For instance, although hospitalizations were defined differently in the two registries (hospitalizations due to any reason were considered in the US CFFPR, whereas only hospitalizations due to pulmonary exacerbations were considered in the UK CFR), the patterns observed were similar between the two registries, and the difference in definitions is not expected to impact the conclusions of the study since most hospitalizations in this population are driven by pulmonary exacerbations \[[@CR4], [@CR13]\]

This study is not without limitations inherent to observational research in general. These include lack of standardized assessment and visit schedules as well as a lack of precise dates for treatment and event occurrences. Additionally, because uptake of ivacaftor in eligible patients was so high, we used a concurrent comparator cohort with different genotypes but comparable disease severity \[[@CR8], [@CR14], [@CR15]\]. Although patients were matched for age, sex, and *CFTR* genotype severity, the difference in genotypes between cohorts may have impacted patients' prognoses in unknown ways. Patients' baseline characteristics did not suggest any such difference in baseline prognoses, and subsequent analyses of outcomes were stratified by age, sex, and percent predicted forced expiratory volume in 1 s to mitigate potential confounding factors \[[@CR7], [@CR8]\]; however, the possibility of confounding factors must be acknowledged. There were also high attrition rates in the last 2 years of follow-up in the US CFFPR comparator cohort due to the availability of lumacaftor/ivacaftor therapy for patients homozygous for the *F508del* mutation (resulting in their exclusion from this study). However, it is important to note that this attrition most likely resulted in an underestimation of the ivacaftor treatment benefit due to the fact that the excluded patients tended to be those who were older and had more severe disease \[[@CR8]\].

Real-world research can be complementary to clinical trials, illustrating outcomes among patients receiving ivacaftor in real-world practice. This study relied on data from two registries, which used distinct data-capture methodologies. Despite this, we were able to make use of the data set from each registry to analyze comparable outcomes and obtain confirmation that the trends we observed were consistent. In addition, trends observed from these real-world outcomes are extremely consistent with outcomes from several prior studies evaluating ivacaftor treatment \[[@CR7], [@CR8]\].

Selection of comparator groups in CF research can be challenging because there are many CF-causing *CFTR* mutations, and the burden of illness varies between genotypes \[[@CR14]\]. In future research of novel CFTR modulators indicated for broader patient populations, identification of concurrent comparators may not be feasible, and alternative approaches, such as historical comparators, may need to be explored. In addition, continuity of and adherence to therapy and the possibility of patients switching between different CFTR modulators will be important considerations.

Conclusions {#Sec8}
===========

Overall, patients treated with ivacaftor had consistently favorable clinical outcomes relative to their untreated comparators, and no new safety concerns were identified. These data demonstrate the long-term impact of highly effective CFTR modulation with ivacaftor.Fig. 1Study design. US ivacaftor patient cohorts analyzed in the annual cross-sectional safety analyses and longitudinal disease progression analyses are shown. Comparator patients were matched to ivacaftor-treated patients (5:1) for age, sex, and *CFTR* genotype severity. A similar approach was used for UK patients. ^a^Volkova et al. \[[@CR8]\]. ^b^Bessonova et al. \[[@CR7]\]
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